Statistical Approaches to Composite Endpoints

Affiliations

Editorial

William S Weintraub. JACC Cardiovasc Interv. 2016.

. 2016 Nov 28;9(22):2289-2291.

doi: 10.1016/j.jcin.2016.08.047.

¹ Christiana Care Health System, Newark, Delaware. Electronic address: wweintraub@christianacare.org.

No abstract available

Keywords: composite endpoints; outcomes; statistics.

Comment on

Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry.
Capodanno D, Gargiulo G, Buccheri S, Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PE, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Leon MB, Moses JW, Fajadet J, Lefèvre T, Morice MC, Erglis A, Alfieri O, Serruys PW, Colombo A, Tamburino C; DELTA Investigators. Capodanno D, et al. JACC Cardiovasc Interv. 2016 Nov 28;9(22):2280-2288. doi: 10.1016/j.jcin.2016.08.025. JACC Cardiovasc Interv. 2016. PMID: 27884354

1. Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920. - PMC - PubMed
1. Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA. 2010;303:267–8. - PubMed
1. Freiman JA, Chalmers TC, Smith H, Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials. N Engl J Med. 1978;299:690–4. - PubMed
1. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366:54–63. - PubMed
1. Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67:353–61. - PubMed